Skip to main contentAI and Advanced
/
ALIVUS · NSEBSE SENSEX77,537.72+0.82%BSE |
NIFTY 5024,231.85+0.64%NSE |
NIFTY BANK57,495.9+0.45%NSE |
NIFTY IT30,673.05+0.79%NSE |
NIFTY AUTO29,301.75+0.40%NSE |
NIFTY FMCG47,863.25+0.82%NSE |
NIFTY PHARMA26,416+0.39%NSE |
NIFTY 50023,512.95+0.54%NSE |
AL
NSE · Equity shares · Biotechnology & Drugs2.00 · 0.15%
Alivus Life Sciences ALIVUS
NSE:INR 1,367
BSE:INR 1,315
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for ALIVUS
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,365
Day rangeINR 1,365.6 — INR 1,402.5
52-week rangeINR 819 — INR 1,418
Volume43,976
Market cap16,125.7
P/E23.54
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,551.83
Net Income (INR Cr)564.48
Rev Growth (5 Year %)6.24
EPS Growth (5 Year %)9.85
P/E Ratio23.54
EPS47.47
Research path: Interpret Alivus Life Sciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ALIVUSAlivus Life Sciences1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 3,982.9 | 3,411.45 | 2,850.41 |
| Cash Equivalents | 1.98 | 25.02 | 269.6 |
| Other Liabilities Total | 36.15 | 18.54 | 15.77 |
| Accrued Expenses | 29.91 | 34.28 | 28.43 |
| Common Stock Total | 24.55 | 24.51 | 24.51 |
| Other Current Assets Total | 69.81 | 0.3 | 0.7 |
| Total Assets | 3,982.9 | 3,411.45 | 2,850.41 |
| Current Portof LT Debt/Capital Leases | 7.98 | 5.65 | 2.39 |
| Total Equity | 3,332.13 | 2,817.37 | 2,332.32 |
| Long Term Investments | 6.79 | 0.08 | 0.08 |
| Retained Earnings(Accumulated Deficit) | 3,307.59 | 1,787.15 | 1,302.86 |
| Total Common Shares Outstanding | 12.27 | 12.25 | 12.25 |
| Tangible Book Valueper Share Common Eq | 269.05 | 228.31 | 189.14 |
| Total Liabilities | 650.77 | 594.08 | 518.09 |
| Total Debt | 56.77 | 56.61 | 17.15 |
| Short Term Investments | 812.67 | 477.61 | Not available |
| Cashand Short Term Investments | 814.65 | 548.68 | 301.41 |
| Total Receivables Net | 1,072.96 | 1,101.72 | 931.95 |
| Deferred Income Tax | 57.79 | 54.43 | 48.79 |
| Accounts Receivable-Trade Net | 1,072.96 | 969.74 | 765.43 |
| Property/Plant/Equipment Total-Net | 1,291.38 | 1,036.92 | 896.2 |
| Total Current Liabilities | 508.04 | 470.16 | 438.77 |
| Total Inventory | 691.93 | 682.2 | 681.13 |
| Accounts Payable | 372.37 | 390.46 | 368.66 |
| Other Currentliabilities Total | 97.78 | 39.77 | 39.3 |
| Total Long Term Debt | 48.79 | 50.96 | 14.76 |
| Intangibles Net | 29.93 | 19.94 | 14.85 |
| Other Long Term Assets Total | 5.44 | 6.37 | 11.03 |
| Note Receivable-Long Term | 0 | 12.99 | 12.26 |
| Total Current Assets | 2,649.36 | 2,335.16 | 1,916 |
| Capital Lease Obligations | 48.79 | 50.96 | 14.76 |
| Accumulated Depreciation Total | Not available | -253.73 | -199.36 |
| Prepaid Expenses | Not available | 2.26 | 0.81 |
| Additional Paid-In Capital | Not available | 1,005.72 | 1,004.96 |
| Cash | Not available | 46.04 | 31.82 |
| Property/Plant/Equipment Total-Gross | Not available | 1,196.4 | 994.37 |
| Notes Payable/Short Term Debt | Not available | 0 | 0 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio4.24
Price to Sale Ratio6.32
Margins
Operating Margin 12m28.26
Operating Margin 5y Avg27.13
Net Profit Margin 12m23.28
Net Profit Margin 5y20.92
Yield
Dividend Yield %0.38
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk30.08
Analyst consensus
ConsensusStrong Buy
Consensus score1.50
Analyst opinions4
Strong Sell count0
Sell count0
Hold count0
Buy count2
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 74.87%
- FII
- 5.54%
- MF
- 5.65%
- Other
- 13.94%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Jaguar Health (NASDAQ: JAGX) signs new crofelemer manufacturing pact - Stock TitanMarket news · 15 Jul 2026, 1:45 am
Jaguar Health (NASDAQ: JAGX) signs new crofelemer manufacturing pact Stock Titan
Alivus Life Sciences Ltd Sees Technical Momentum Shift Amid Mixed Indicator Signals - MarketsMojoMarket news · 14 Jul 2026, 4:27 pm
Alivus Life Sciences Ltd Sees Technical Momentum Shift Amid Mixed Indicator Signals MarketsMojo
Alivus Life Sciences Ltd Technical Momentum Shifts to Bullish Amid Strong Returns - MarketsMojoMarket news · 13 Jul 2026, 8:04 am
Alivus Life Sciences Ltd Technical Momentum Shifts to Bullish Amid Strong Returns MarketsMojo
Alivus Life Sciences Ltd is Rated Hold - MarketsMojoMarket news · 11 Jul 2026, 10:46 am
Alivus Life Sciences Ltd is Rated Hold MarketsMojo
Broad-Based Technical Strength Lifts Alivus Life Sciences Ltd to 52-Week High of Rs 1193.3 - MarketsMojoMarket news · 2 Jul 2026, 11:14 am
Broad-Based Technical Strength Lifts Alivus Life Sciences Ltd to 52-Week High of Rs 1193.3 MarketsMojo
ALIVUS Forecast — Price Target — Prediction for 2027 - TradingViewMarket news · 27 Jun 2026, 2:06 am
ALIVUS Forecast — Price Target — Prediction for 2027 TradingView
Corporate actions
Events
- board MeetingsQuarterly Results
- dividendRs.5.0000 per share(250%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.5.0000 per share(250%)Final Dividend
- board MeetingsQuarterly Results
ShareKeyX Community
Discussion and sentiment for Alivus Life Sciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as antifungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ALIVUS
- BSE Code
- 543322
Questions
Stock FAQ
What is the symbol and ISIN of Alivus Life Sciences?
Alivus Life Sciences has the symbol ALIVUS and ISIN - INE03Q201024.
What is the current price of Alivus Life Sciences?
Alivus Life Sciences is currently trading at INR 1,367.00.
What are the year high and year low of Alivus Life Sciences?
Alivus Life Sciences has a year high of INR 1,418.00 and a year low of INR 819.00.
What is the market capitalization of Alivus Life Sciences?
Alivus Life Sciences has a market capitalization of INR 16,125.70 crore.
What is the P/E ratio of Alivus Life Sciences?
Alivus Life Sciences has a P/E ratio of 23.54.
What is the dividend yield of Alivus Life Sciences?
Alivus Life Sciences has a dividend yield of 0.38%.
How is the financial performance of Alivus Life Sciences based on revenue, net income, and EPS?
Alivus Life Sciences has revenue of INR 2,551.83 crore, net income of INR 564.48 crore, and EPS of INR 50.61.
What is the book value of Alivus Life Sciences?
Alivus Life Sciences has a book value of NA.
What is the debt-to-equity ratio of Alivus Life Sciences?
Alivus Life Sciences has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Alivus Life Sciences?
Alivus Life Sciences has a price-to-book ratio of NA and a price-to-sales ratio of 6.32.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.